AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

EyePoint Pharmaceuticals ... (EYPT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.36

-0.11 (-1.70%)

At close: Feb 20, 2025, 3:59 PM

6.35

-0.16%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	6.35
Market Cap	434.08M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.99
PE Ratio (ttm)	-3.2
Forward PE	n/a
Analyst	Buy

Ask	6.62
Volume	610,378
Avg. Volume (20D)	900,349
Open	6.45
Previous Close	6.47
Day's Range	6.23 - 6.65
52-Week Range	5.90 - 29.31
Beta	undefined

About EYPT

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 27, 2005

Employees 121

Stock Exchange NASDAQ

Ticker Symbol EYPT

Website https://eyepointpharma.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for EYPT stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 355.97% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

EyePoint Pharmaceuticals Inc. is scheduled to release its earnings on Mar 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+2.36%

EyePoint Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription

3 months ago

+27.58%

EyePoiint Pharmaceuticals shares are trading higher after the company showed early trial data for DURAVYU for diabetic macular edema and announced improving vision and anatomy.

News

3 weeks ago · seekingalpha.com

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ongoin...